P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia

Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with chronic myeloid leukemia (CML) and confers significant benefit for most patients; however, a substantial number of patients are either initially refractory or develop resistance. Point mutations within the ABL...

Descripción completa

Detalles Bibliográficos
Autores principales: Cang, Shundong, Liu, Delong
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567340/
https://www.ncbi.nlm.nih.gov/pubmed/18828913
http://dx.doi.org/10.1186/1756-8722-1-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567340/
https://www.ncbi.nlm.nih.gov/pubmed/18828913
http://dx.doi.org/10.1186/1756-8722-1-15

Ejemplares similares